December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Efficacy and Safety of Bimatoprost 0.03% (LUMIGAN) in a Large-Scale, Open-Label Clinical Trial
Author Affiliations & Notes
  • DA Lee
    Penn State Coll Med Milton S Hershey Med Ctr Hershey PA
  • R Gross
    Ophthalmology Baylor College of Medicine Houston TX
  • TK MundorfLumigan Early Experience Study Group
    Presbyterian Medical Tower Charlotte NC
  • Footnotes
    Commercial Relationships    D.A. Lee, Allergan, Inc. F; R. Gross, Allergan, Inc. F; Alcon Laboratories, Inc. F; Merck & Co., Inc. F; Pharmacia & Upjohn F; T.K. Mundorf, Allergan, Inc. F; Santen, Inc. F; Senju F.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4105. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      DA Lee, R Gross, TK MundorfLumigan Early Experience Study Group; Efficacy and Safety of Bimatoprost 0.03% (LUMIGAN) in a Large-Scale, Open-Label Clinical Trial . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4105.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the safety and efficacy of bimatoprost 0.03% for the treatment of glaucoma and ocular hypertension in the "real-life" clinical practices of physicians throughout the United States and Puerto Rico. Method: Two-month, open-label, non-comparative surveillance trial. Included patients had a diagnosis of glaucoma or ocular hypertension and were in need of additional intraocular pressure (IOP)-lowering or were intolerant of other ocular hypotensive medications. Results: 6767 patients were enrolled at 1439 clinical sites. Physicians prescribed bimatoprost as monotherapy for patients not using IOP-lowering medications at baseline (n=1946, 28.8%), as adjunctive therapy (n=2640, 39.0%), or as replacement therapy (n=2117, 31.3%). After 2 months of bimatoprost therapy, the mean IOP reduction in patients newly diagnosed with glaucoma was 7.9 mm Hg (30.7%, P<.001). Among patients who added bimatoprost to their ongoing treatment regimens, the mean additional IOP reduction with bimatoprost was 5.0 mm Hg (21.3%, P<.001). After 2 months of bimatoprost replacement therapy, the mean IOP reduction from baseline on the previous therapy was 4.2 mm Hg (18.6%, P<.001). Patients were significantly more likely to achieve every target level of IOP from < 12 to < 18 mm Hg after 2 months of bimatoprost therapy than at baseline (P<.001). For example, 32.5% of patients achieved a target of <15 mm Hg at the month 2 evaluation, compared with 5.6% of patients at baseline (P<.001). Conclusion: Bimatoprost is highly effective as monotherapy, adjunctive therapy, and replacement therapy for glaucoma and ocular hypertension patients in "real-life" clinical practice. Bimatoprost allows patients to reach low target IOP levels.

Keywords: 444 intraocular pressure • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 514 pharmacology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.